Drugs obtained by biotechnology processing

• Type: Another Publication in an International Scientific Journal
• Date: 2011

Authors

Hugo Almeida (Author) Other; Maria Helena Amaral (Author) FFUP; Paulo Lobao (Author) FFUP

Journal

Title: Brazilian Journal of Pharmaceutical Sciences

Vol. 47 No. 2

Pages: 199-207

ISSN: 1984-8250

Publisher: Universidade de São Paulo

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 3 Citations

Scientific classification

FOS: Medical and Health sciences > Basic medicine

Other information

Authenticus ID: P-002-SGP

Abstract (EN): In recent years, the number of drugs of biotechnological origin available for many different diseases has increased exponentially, including different types of cancer, diabetes mellitus, infectious diseases (e.g. AIDS Virus / HIV) as well as cardiovascular, neurological, respiratory, and autoimmune diseases, among others. The pharmaceutical industry has used different technologies to obtain new and promising active ingredients, as exemplified by the fermentation technique, recombinant DNA technique and the hybridoma technique. The expiry of the patents of the first drugs of biotechnological origin and the consequent emergence of biosimilar products, have posed various questions to health authorities worldwide regarding the definition, framework, and requirements for authorization to market such products.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9